Cholesterol emboli syndrome medical therapy

Jump to navigation Jump to search

Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome medical therapy

CDC on Cholesterol emboli syndrome medical therapy

Cholesterol emboli syndrome medical therapy in the news

Blogs on Cholesterol emboli syndrome medical therapy

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Overview

Some pharmacologic medical therapies that can be effective for cholesterol emboli syndrome include statins, corticosteroids, colchicine, cyclophosphamide and IL1 antagonists.

Medical Therapy

References

  1. Ozkok, Abdullah (2019). "

    Cholesterol-embolization syndrome: current perspectives

    ". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048.
  2. Akdim, Fatima; van Leuven, Sander; P. Kastelein, John; G. Stroes, Erik (2007). "Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?". Current Pharmaceutical Design. 13 (10): 1003–1012. doi:10.2174/138161207780487548. ISSN 1381-6128.
  3. Tousoulis, Dimitris; Psarros, Costas; Demosthenous, Michael; Patel, Rikhil; Antoniades, Charalambos; Stefanadis, Christodoulos (2014). "Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease". Journal of the American College of Cardiology. 63 (23): 2491–2502. doi:10.1016/j.jacc.2014.01.054. ISSN 0735-1097.
  4. Woolfson, Robin G; Lachmann, Helen (1998). "Improvement in renal cholesterol emboli syndrome after simvastatin". The Lancet. 351 (9112): 1331–1332. doi:10.1016/S0140-6736(05)79058-9. ISSN 0140-6736.
  5. "Cholesterol crystal embolization (CCE): Improvement of renal function with high-dose corticosteroid treatment Desai M, Ram R, Prayaga A, Dakshinamurty K V - Saudi J Kidney Dis Transpl".
  6. Stabellini N, Cerretani D, Russo G, Rizzioli E, Gilli P (2002). "[Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy]". G Ital Nefrol (in Italian). 19 (1): 18–21. PMID 12165941.
  7. Yücel, A. E.; Kart-Köseoglu, H.; Demirhan, B.; Özdemir, F. N. (2005). "Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases". Rheumatology International. 26 (5): 454–460. doi:10.1007/s00296-005-0012-4. ISSN 0172-8172.
  8. . doi:10.1016/j.atherosclerosis.2017.12.02. Missing or empty |title= (help)
  9. Robertson, Stacy; Martínez, Gonzalo J.; Payet, Cloe A.; Barraclough, Jennifer Y.; Celermajer, David S.; Bursill, Christina; Patel, Sanjay (2016). "Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation". Clinical Science. 130 (14): 1237–1246. doi:10.1042/CS20160090. ISSN 0143-5221.


Template:WikiDoc Sources